Popular Trials
Dupilumab and Milk OIT for Cow's Milk Allergy
This trial tests if using dupilumab with milk oral immunotherapy (OIT) can help people aged 4 to 50 who are allergic to cow's milk. Dupilumab reduces allergic reactions, and OIT helps the body get used to milk. The goal is to see if this combination makes it safer and more effective for these individuals to consume milk. Dupilumab has been approved for treating certain skin conditions and has shown promise in other allergic conditions.
Beta-lactam Antibiotic
Amoxicillin for Penicillin Allergy
This trial aims to determine if patients with a reported penicillin allergy can safely receive penicillin or its derivatives. Patients will be asked specific questions to determine their risk of an allergic reaction. Low
Immunotherapy
Peanut SLIT-Tablet for Peanut Allergy
This trial tests a tablet containing small amounts of peanut protein taken under the tongue. It aims to help people with peanut allergies become less sensitive to peanuts. Participants will take gradually increasing doses to see if their tolerance improves.
Popular Filters
Trials for Food Allergy Patients
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Low-Dose Multi-Oral Immunotherapy for Food Allergies
This trial tests if giving nut-allergic children very small amounts of multiple nuts can help them tolerate these nuts without allergic reactions. The goal is to make their immune system get used to the nuts over time.
Behavioral Intervention
Food Allergy Mastery Program for Food Allergies
This trial will examine a new program to help teens with food allergies learn how to manage their condition, with education, problem-solving, communication, and peer support.
Trials for Peanut Allergy Patients
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Oral Immunotherapy for Peanut Allergy
This trial studies how gradually eating small amounts of peanut can help people with peanut allergies reduce their allergic reactions. It focuses on individuals aged 6 months to 65 years and aims to improve their quality of life and predict who will benefit most from this treatment. A specific preparation of peanut allergen was approved for younger patients with a peanut allergy.
Microbiome Modulator
VE416 for Peanut Allergy
This trial tests VE416, a capsule with friendly bacteria, combined with an antibiotic and peanut flour, to help people with peanut allergies. The bacteria activate in the intestines and may help prevent allergic reactions. The goal is to see if this combination is safe and effective.
Phase 3 Trials
Long-term Ligelizumab for Food Allergy
This trial is testing the long-term safety and effectiveness of ligelizumab, a medication for food allergies. Ligelizumab is a new type of medication that has shown promise in treating certain allergic conditions and is now being tested for food allergies. It works by blocking proteins that trigger allergic reactions, helping to prevent symptoms. It is being tested on people who have already participated in an earlier study of this medication.
Hormone Therapy
Androgen Ablation Therapy + Chemotherapy for Prostate Cancer
This trial is studying androgen-ablation therapy and docetaxel to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Dexamethasone Methods for Preventing Allergic Reactions to Chemotherapy
This trial tests three different ways to prevent allergic reactions in women with gynecologic cancers who are treated with paclitaxel. The methods involve using steroids and antihistamines before the treatment. The goal is to find out which method works best to keep patients safe from allergic reactions. Paclitaxel is a plant product highly active in numerous cancers, but it has a significant incidence of hypersensitivity reactions, which are typically managed with steroids and antihistamines.
Checkpoint Inhibitor
Pembrolizumab + ADT for Prostate Cancer
This trial will test whether a combination of drugs is better than placebo at extending radiographic progression-free survival and overall survival for men with metastatic hormone-sensitive prostate cancer.
Trials With No Placebo
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Oral Immunotherapy for Peanut Allergy
This trial studies how gradually eating small amounts of peanut can help people with peanut allergies reduce their allergic reactions. It focuses on individuals aged 6 months to 65 years and aims to improve their quality of life and predict who will benefit most from this treatment. A specific preparation of peanut allergen was approved for younger patients with a peanut allergy.
Immunotherapy
Low-Dose Multi-Oral Immunotherapy for Food Allergies
This trial tests if giving nut-allergic children very small amounts of multiple nuts can help them tolerate these nuts without allergic reactions. The goal is to make their immune system get used to the nuts over time.
Barrier Cream
Skin Barrier Cream + Fluticasone Propionate for Eczema
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeramâ„¢ has been previously tested for preventing eczema in infants with a family history of allergic disease.
View More Related Trials
Frequently Asked Questions
Introduction to penicillin allergy
What are the top hospitals conducting penicillin allergy research?
When it comes to tackling the complex issue of penicillin allergies, several leading hospitals in the United States are at the forefront of groundbreaking research and clinical trials. Massachusetts General Hospital in Boston stands out with four currently active trials dedicated to understanding and managing penicillin allergy, aiming to improve patient care for those affected by this condition. Similarly, Icahn School of Medicine at Mount Sinai in New york is making significant contributions with its own set of four ongoing trials focused on exploring new approaches to address penicillin allergies. In El Paso, Western Sky Medical Research is actively conducting three clinical trials centered around penicillin allergy management.
Moreover, Novartis Investigative Sites located in both Louisville and Baltimore have also joined forces by initiating two active clinical trials each solely focusing on penicillin allergy research; these sites aim to contribute towards a better understanding of this prevalent condition while seeking innovative solutions.
Although no historical data for previous studies exists yet within these specific institutions regarding penicillin allergy, their commitment and dedication towards addressing this important medical concern offer hope for patients who suffer from adverse reactions or complications associated with the use of antibiotics like penicillin. With ongoing advancements through these cutting-edge trials across different locations nationwide, there is promising potential not only for improved treatment options but also a deeper comprehension of why some individuals experience allergic reactions to one of medicine's most widely used drugs
Which are the best cities for penicillin allergy clinical trials?
When it comes to penicillin allergy clinical trials, several cities have emerged as key players in research. Chicago, Illinois leads the way with 20 ongoing trials investigating treatments like the iREACH CDS Tool, Prebiotic, and Tri-lipid skin barrier cream (Epiceram). Following closely behind is Boston, Massachusetts with 8 active trials exploring interventions such as Peanut SLIT-tablet and Ligelizumab 120 mg. New york City also contributes to this field with 7 ongoing studies focusing on DBV1605 and Ligelizumab 120 mg among others. Baltimore, Maryland and Miami, Florida round out the list with each city hosting 5 active trials that investigate various treatment options for penicillin allergy. These cities serve as hubs for cutting-edge research in an effort to improve outcomes for individuals living with this allergic condition.
Which are the top treatments for penicillin allergy being explored in clinical trials?
In the realm of penicillin allergy, clinical trials are currently focusing on several promising treatments. One standout contender is cetirizine, being explored in four active trials for this specific condition. Another potential solution making strides is montelukast, with three ongoing studies dedicated to investigating its effectiveness against penicillin allergies. Finally, a third notable treatment under scrutiny is desensitization therapy—a method that aims to increase tolerance to penicillin over time. As researchers delve deeper into these avenues, hope grows for finding effective solutions and improving the lives of individuals with penicillin allergies.
What are the most recent clinical trials for penicillin allergy?
Recent clinical trials offer valuable insights into the treatment of penicillin allergy, providing hope for individuals affected by this condition. A Phase 3 trial focused on ligelizumab at a dosage of 120 mg showcased promising results in addressing penicillin allergies. Another study investigated the efficacy of low-dose remibrutinib (Phase 2) in managing penicillin allergies with encouraging outcomes. Additionally, a Phase 4 trial explored the benefits of oral challenges as a means to evaluate and potentially overcome penicillin allergies. Furthermore, early-stage research involving peanut sublingual immunotherapy (SLIT-tablet) and abrocitinib at a dosage of 100mg demonstrated potential therapeutic avenues for individuals experiencing penicillin allergies. These recent developments hold great promise for improving patient care and quality of life related to penicillin allergy management.
What penicillin allergy clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of penicillin allergy research. These trials focused on investigating new approaches to address this common allergic reaction. Notably, a trial sponsored by an undisclosed organization concluded in October 2021 and showcased promising results for potential treatments. Additionally, another trial conducted by a separate group was completed in September 2021, further adding to our understanding of penicillin allergies and potential interventions. These advancements highlight the diligent efforts of researchers working towards improving patient outcomes and management strategies for those with penicillin allergies.